

Titolo:	Studio di fase 2 per valutare l'efficacia e la sicurezza di selinexor in monoterapia in soggetti con mielofibrosi e trombocitopenia moderata naïve agli inibitori di JAK
Codice studio	XPORT-MF-044
Patologia:	mielofibrosi
Tipo di Studio:	interventistico con farmaco
Tipologia	profit
Fase:	2
Principali criteri di inclusione:	<ul style="list-style-type: none"> • A diagnosis of MF or post-ET or post-PV MF according to the 2016 World • Measurable splenomegaly during the screening period as demonstrated by spleen volume of ≥ 450 cm³ by MRI or CT scan • DIPSS risk category of intermediate-1 with symptoms, or intermediate-2, or highrisk. • Platelet count of 50 to $< 100 \times 10^9$ /L without platelet transfusion within 7 days prior to the first dose of selinexor. • Active symptoms of MF as determined by presence of at least 2 symptoms with a score ≥ 3 or total score of ≥ 10 at screening
Principali criteri di esclusione:	<ul style="list-style-type: none"> • More than 10% blasts in peripheral blood or bone marrow • Previous treatment with JAK inhibitors for MF
Struttura	SCDU Ematologia e Terapie Cellulari
Contatto	Prof.ssa Daniela Cilloni daniela.cilloni@unito.it